Mittermayr, T. (2024): Appraisal Board (Test). DSD: Bewertungsboard I.

Strohmaier, C. and Zechmeister-Koss, I. (2024): Threshold values in health economic evaluations and decision-making. HTA-Projektbericht 163.

Kern, J. and Reinsperger, I. and Hofer, V. (2024): Mental health screening of adults in primary care. HTA-Projektbericht 159.

Grössmann-Waniek, N. and Strohmaier, C. and Riegelnegg, M. (2024): Oncological Breast Cancer Care in Selected European Countries – Cross-sectoral cancer care models. HTA-Projektbericht 162.

Riegelnegg, M. and Giess, D. and Goetz, G. (2024): Artificial Intelligence in health care with a focus on hospitals: Methodological considerations for Health Technology Assessment. A Scoping Review. HTA-Projektbericht 164.

Wolf, S. and Kern, J. (2024): Strategies for reducing weight stigmatisation towards people with overweight or obesity in the healthcare system. HTA-Projektbericht 160.

Zechmeister-Koss, I. and Kern, J. and Edlinger, M. (2024): Uptake of Mental Health Benefits in Women Before and During the Perinatal Period: An Analysis of Austrian Health Insurance Data. HTA-Projektbericht 154.

Jeindl, R. and Mayer-Ferbas, J. (2024): Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets. Rapid Review Nr.: 015.

Rothschedl, E. and Malikova, E. and Grössmann, N (2024): Daratumumab (Darzalex®) with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). Fact Sheet Nr. 191.

Rothschedl, E. and Grössmann, N. (2024): Serplulimab (Hetronifly®) with carboplatin and etoposide for the first‑line treatment of extensive‑stage small cell lung cancer (ES-SCLC). Fact Sheet Nr. 192.

Rothschedl, E. and Malikova, E. and Grössmann, N. (2024): Mirvetuximab soravtansine (Elahere®) for the treatment of adults with folate receptor-alpha (FRα) positive epithelial ovarian, fallopian tube and primary peritoneal cancer. Fact Sheet Nr. 193.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) with chemoradiotherapy (CRT) for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer. Fact Sheet Nr. 194.

Rothschedl, E and Malikova, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) for the treatment of adults with endometrial carcinoma. Fact Sheet Nr. 195.

Erdos, J. and Schmidt, L. and Reinsperger, I. (2024): Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer. HTA-Projektbericht 107/ 1. Update.

Rothschedl, E. and Grössmann, N. (2024): Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC). Fact Sheet Nr. 184.

Rothschedl, E. and Grössmann, N. (2024): Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC). Fact Sheet Nr. 185.

Rothschedl, E. and Grössmann, N. (2024): Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Fact Sheet Nr. 186.

Rothschedl, E. and Grössmann, N. (2024): Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 187.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma. Fact Sheet Nr. 188.

Rothschedl, E. and Grössmann, N. (2024): Amivantamab (Rybrevant®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 189.

Huic, M. and Erdos, J. and Wild, C. (2024): Point of Care Tests (POCT): D-Dimer and Troponin. HTA-Projektbericht 124/ 1. Update.

Rothschedl, E. and Grössmann, N. (2024): Erdafitinib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC). Fact Sheet Nr. 180.

Rothschedl, E. and Grössmann, N. (2024): Odronextamab (Ordspono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B‑cell lymphoma (r/r DLBCL). Fact Sheet Nr. 181.

Rothschedl, E. and Grössmann, N. (2024): Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC), followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair deficient (dMMR) or in combination with olaparib (Lynparza®) in EC that is mismatch repair proficient (pMMR). Fact Sheet Nr. 182.

Rothschedl, E. and Grössmann, N. (2024): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL). Fact Sheet Nr. 183.

Jeindl, R. and Mayer-Ferbas, J. (2024): CAR-based immunotherapy with a focus on CAR-NK cells. Rapid Review Nr.: 013.

Mayer-Ferbas, J. and Jeindl, R. (2024): Skin cancer prevention: Guideline recommendations for primary and secondary prevention. Rapid Review Nr.: 014.

Rothschedl, E. and Grössmann, N. (2024): Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first‑line treatment of metastatic non‑small‑cell lung cancer (NSCLC). Fact Sheet Nr. 177.

Rothschedl, E. and Grössmann, N. (2024): Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 178.

Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 179.

Rothschedl, E. and Grössmann, N. (2024): Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC). Fact Sheet Nr. 171.

Rothschedl, E. and Grössmann, N. (2024): Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2‑negative locally advanced or metastatic breast cancer. Fact Sheet Nr. 172.

Rothschedl, E. and Grössmann, N. (2024): Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK‑positive non‑small cell lung cancer (NSCLC). Fact Sheet Nr. 173.

Rothschedl, E. and Grössmann, N. (2024): Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. Fact Sheet Nr. 174.

Rothschedl, E. and Grössmann, N. (2024): Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion. Fact Sheet Nr. 175.

Rothschedl, E. and Grössmann, N. (2024): Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first‑line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations. Fact Sheet Nr. 176.

Jeindl, R. and Mayer-Ferbas, J. (2024): Use of telepathology for intraoperative frozen section examination. Rapid Review Nr.: 012.

Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 164.

Rothschedl, E. and Grössmann, N. (2024): Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma. Fact Sheet Nr. 165.

Rothschedl, E. and Grössmann, N. (2024): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 166.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC). Fact Sheet Nr. 167.

Rothschedl, E. and Grössmann, N. (2024): Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Fact Sheet Nr. 168.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours. Fact Sheet Nr. 169.

Rothschedl, E. and Grössmann, N. (2024): Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC). Fact Sheet Nr. 170.

Erdos, J. and Riegelnegg, M. and Sawalha, R. (2024): Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia. Decision Support Document 140.

Nicolopoulos, K. and Riegelnegg, M. and Hollyoak, R. and Vreugdenburg, T. (2024): Thermoablation for benign thyroid nodules. Decision Support Document 141.

Semlitsch, T. and Krenn, C. (2024): Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD). 3rd Update. Decision Support Document 24/ 3. Update 2024.

Goetz, G. and Giess, D. and Kern, J. (2024): Renal denervation (RDN) in patients with treatment resistant hypertension. Decision Support Document 45/ 2. Update 2024.

Jeindl, R. and Wolf, S. (2024): Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023. Rapid Review Nr.: 011.

Wild, C. and Fabian, D. (2024): The Role of Public Contributions to the Development of Health Innovations. HTA-Projektbericht 158.

Wild, C. and Erdos, J. and Jeindl, R. (2024): Biomarkers in Parkinson's Disease. Rapid Review Nr.: 010.

AIHTA, HTA Austria (2024): Annual Report 2023.

Scott, A. and Kern, J. and Vreugdenburg, T. (2024): Caval valve implantation (CAVI) for severe tricuspid regurgitation. Decision Support Document 139.

Mayer-Ferbas, J. and Jeindl, R. (2024): Liposuction for the removal of subcutaneous (large) lipomas. Rapid Review Nr.: 009.

Rothschedl, E. and Grössmann, N. (2024): Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies. Update September 2024. Fact Sheet Nr. 162.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Update September 2024. Fact Sheet Nr. 163.